Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.61 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | CCR2 | P41597 | 3/20 | 0.52 |
| ▸ | KDM1A | O60341 | 1/20 | 0.52 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.51 |
| ▸ | HPGDS | O60760 | 1/20 | 0.51 |
| ▸ | TACR2 | P21452 | 1/20 | 0.47 |
| ▸ | TACR1 | P25103 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4077361 | 1.00 | RAB9A (0.68) | RAB9AALDH1A1KDM4EDDB1CRBN | |
| SCHEMBL4078575 | 1.00 | RAB9A (0.68) | RAB9AALDH1A1KDM4EDDB1CRBN | |
| SCHEMBL8381645 | 0.95 | RAB9A (0.75) | RAB9AALDH1A1KDM4EDDB1CRBN | |
| SCHEMBL15087624 | 0.95 | RAB9A (0.75) | RAB9AALDH1A1KDM4EDDB1CRBN | |
| SCHEMBL3730396 | 0.91 | DDB1 (0.64) | RAB9AALDH1A1KDM4EDDB1CRBN | |
| SCHEMBL4134276 | 0.91 | DDB1 (0.64) | RAB9AALDH1A1KDM4EDDB1CRBN | |
| SCHEMBL14856310 | 0.85 | RAB9A (0.92) | RAB9AALDH1A1KDM4EDDB1CRBN | |
| SCHEMBL14856126 | 0.85 | RAB9A (0.69) | RAB9AALDH1A1KDM4EDDB1CRBN | |
| SCHEMBL15087627 | 0.85 | RAB9A (0.92) | RAB9AALDH1A1KDM4EDDB1CRBN | |
| SCHEMBL14856370 | 0.85 | RAB9A (0.69) | RAB9AALDH1A1KDM4EDDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130172318-A1 | ANTI-INFLAMMATORY AGENTS | GRAINGER DAVID JOHN (GB) | 2013-07-04 | — | — | US | disclosed |
| EP-2580196-A1 | ANTI-INFLAMMATORY AGENTS | Cambridge Enterprise Ltd. (GB) | 2013-04-17 | — | — | EP | disclosed |
| WO-2011154696-A1 | ANTI-INFLAMMATORY AGENTS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2011-12-15 | — | — | WO | disclosed |
| US-7531657-B2 | Method for preparing sulphostin and analogue thereof or preparation intermediate thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2009-05-12 | — | — | US | disclosed |
| US-20050020834-A1 | Method for preparation of sulphostin and its analogue or intermediates thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-1457494-A1 | PROCESSES FOR PREPARATION OF SULPHOSTIN AND ITS ANALOGUES OR INTERMEDIATES THEREOF | Nippon Kayaku Kabushiki Kaisha (JP) | 2004-09-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020834-A1 | Method for preparation of sulphostin and its analogue or intermediates thereof | SOST, PTMS, FGF23 | RAB9A 3013/4885ALDH1A1 3724/4885KDM4E 3668/4885 |
| US-20130172318-A1 | ANTI-INFLAMMATORY AGENTS | IL6, TNF, IL1B | RAB9A 3124/4885ALDH1A1 196/4885KDM4E 1765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.